Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories
15th National Conference of the IAOMFP, Chennai, 2006
Abstract
Abstracts from current literature
Acne in India: Guidelines for management - IAA Consensus Document
Addendum
Announcement
Art & Psychiatry
Article
Articles
Association Activities
Association Notes
Award Article
Book Review
Brief Report
Case Analysis
Case Letter
Case Letters
Case Notes
Case Report
Case Reports
Clinical and Laboratory Investigations
Clinical Article
Clinical Studies
Clinical Study
Commentary
Conference Oration
Conference Summary
Continuing Medical Education
Correspondence
Corrigendum
Cosmetic Dermatology
Cosmetology
Current Best Evidence
Current View
Derma Quest
Dermato Surgery
Dermatopathology
Dermatosurgery Specials
Dispensing Pearl
Do you know?
Drug Dialogues
e-IJDVL
Editor Speaks
Editorial
Editorial Remarks
Editorial Report
Editorial Report - 2007
Editorial report for 2004-2005
Errata
Erratum
Focus
Fourth All India Conference Programme
From Our Book Shelf
From the Desk of Chief Editor
General
Get Set for Net
Get set for the net
Guest Article
Guest Editorial
History
How I Manage?
IADVL Announcement
IADVL Announcements
IJDVL Awards
IJDVL AWARDS 2015
IJDVL Awards 2018
IJDVL Awards 2019
IJDVL Awards 2020
IJDVL International Awards 2018
Images in Clinical Practice
In Memorium
Inaugural Address
Index
Knowledge From World Contemporaries
Leprosy Section
Letter in Response to Previous Publication
Letter to Editor
Letter to the Editor
Letter to the Editor - Case Letter
Letter to the Editor - Letter in Response to Published Article
LETTER TO THE EDITOR - LETTERS IN RESPONSE TO PUBLISHED ARTICLES
Letter to the Editor - Observation Letter
Letter to the Editor - Study Letter
Letter to the Editor - Therapy Letter
Letter to the Editor: Articles in Response to Previously Published Articles
Letters to the Editor
Letters to the Editor - Letter in Response to Previously Published Articles
Letters to the Editor: Case Letters
Letters to the Editor: Letters in Response to Previously Published Articles
Medicolegal Window
Messages
Miscellaneous Letter
Musings
Net Case
Net case report
Net Image
Net Letter
Net Quiz
Net Study
New Preparations
News
News & Views
Obervation Letter
Obituary
Observation Letter
Observation Letters
Oration
Original Article
ORIGINAL CONTRIBUTION
Original Contributions
Pattern of Skin Diseases
Pearls
Pediatric Dermatology
Pediatric Rounds
Perspective
Presedential Address
Presidential Address
Presidents Remarks
Quiz
Recommendations
Regret
Report
Report of chief editor
Report of Hon : Treasurer IADVL
Report of Hon. General Secretary IADVL
Research Methdology
Research Methodology
Resident page
Resident's Page
Resident’s Page
Residents' Corner
Residents' Corner
Residents' Page
Retraction
Review
Review Article
Review Articles
Revision Corner
Self Assessment Programme
SEMINAR
Seminar: Chronic Arsenicosis in India
Seminar: HIV Infection
Short Communication
Short Communications
Short Report
Special Article
Specialty Interface
Studies
Study Letter
Supplement-Photoprotection
Supplement-Psoriasis
Symposium - Contact Dermatitis
Symposium - Lasers
Symposium - Pediatric Dermatoses
Symposium - Psoriasis
Symposium - Vesicobullous Disorders
SYMPOSIUM - VITILIGO
Symposium Aesthetic Surgery
Symposium Dermatopathology
Symposium-Hair Disorders
Symposium-Nails Part I
Symposium-Nails-Part II
Tables
Technology
Therapeutic Guidelines
Therapeutic Guidelines - IADVL
Therapeutics
Therapy
Therapy Letter
View Point
Viewpoint
What’s new in Dermatology
View/Download PDF
Net letter
2012:78:3;408-408
doi: 10.4103/0378-6323.95491

Imatinib mesylate induced erythroderma

Swapnil A Sanghavi, Atul M Dongre, Uday S Khopkar
 Department of Skin and VD, Seth G.S. Medical College and KEM Hospital, Parel, Mumbai, Maharashtra, India

Correspondence Address:
Swapnil A Sanghavi
Department of Skin and VD, Seth G.S. Medical College and KEM Hospital, Parel, Mumbai 400 012, Maharashtra
India
How to cite this article:
Sanghavi SA, Dongre AM, Khopkar US. Imatinib mesylate induced erythroderma. Indian J Dermatol Venereol Leprol 2012;78:408
Copyright: (C)2012 Indian Journal of Dermatology, Venereology, and Leprology

Sir,

Imatinib is the first molecularly targeted drug developed for the treatment of Chronic myeloid leukemia (CML) and has achieved remarkable success. It is a tyrosine kinase inhibitor, which is extensively used for treatment of malignancies. Here, we report a case of erythroderma induced by imatinib in a case of CML, which was severe enough to warrant discontinuation of the therapy. Imatinib-induced erythroderma is uncommon in occurrence and only a few reports including one from India have been mentioned in literature. [1]

A 36-year-old woman presented with complaints of redness and itching all over the body, including the face, of the duration of five days. She was a known case of CML diagnosed in 2006 and was treated with hydroxyurea. Her recent drug history revealed that she was on oral imatinib Mesylate 800 mg/day and her skin rash started two days after the initiation of imatinib. Along with skin rash she had low-grade fever of the duration of four days. On further probing, she gave a history of similar type of skin rash 3 months back, which started about 15 days after starting treatment with imatinib; after this, imatinib was discontinued by the hematologist. Following this, the rash subsided completely in one month. The drug was recently restarted at a dose of 800 mg/day following which she redeveloped similar rash with greater severity.

On examination, diffuse erythema with fine scaling was observed all over the body including palm, soles, and face [Figure - 1]. Erythema and scaling were more pronounced over the trunk [Figure - 2] and periorbital region. Her fingernails were hyperpigmented. No significant lymphadenopathy or hepatosplenomegaly was observed in the patient.

Figure 1: Erythema and scaling on the face
Figure 2: Erythroderma over the trunk and extremities

A skin biopsy done from back showed epidermal hyperplasia, foci of parakeratosis, spongiosis, and a few necrotic keratinocytes [Figure - 3]. Dermis showed sparse superficial perivascular infiltrate consisting of lymphocytes and few eosinophils. Her liver function tests, total blood counts including eosinophil count (2%) and renal function tests showed normal results.

Figure 3: Epidermal hyperplasia with parakeratosis, spongiosis, and necrotic keratinocytes (H and E, ×200)

Imatinib was discontinued. She was started on oral antihistaminics and oral prednisolone 40 mg/day. The rash subsided over a period of 7 days [Figure - 4]. Avoidance of imatinib mesylate was advised and the hematologists are now planning to start her on Dasatinib.

Imatinib acts by inhibition of several tyrosine kinase enzymes, including Bcr-Abl tyrosine kinase. [1] It is the initial choice of treatment for most patients with CML.

Figure 4: Erythema and scaling disappeared 7 days after discontinuation of imatinib

Imatinib has been commonly known to cause non-dermatological side effects. The reported incidence of cutaneous reactions to imatinib varies from 9.5% to 69%. [2] Milder skin reactions are more common (30-40%) than the severe ones (2-5%). The drug acts as a dose-dependent inducer of cutaneous adverse reactions with mild reactivity to low or intermediate doses (200-600 mg/day), but severe eruptions to high dose (600-1000 mg/day). The common dermatological side effects include maculopapular eruptions and periorbital edema, which are usually self-limited. Severe cutaneous adverse effects such as Stevens Johnson′s syndrome, toxic epidermal necrolysis, and acute generalized exanthematous pustulosis are uncommon in occurrence. Rare cutaneous eruptions are exfoliative dermatitis, lichenoid reactions, pityriasiform eruptions, psoriasis, and reactivation or induction of porphyria cutanea tarda. [2] Re-pigmentation of gray hair, hyperpigmentation of the nails, [3] and skin hypopigmentation have been reported.

Our extensive literature search revealed only a few case reports of imatinib-induced exfoliative dermatitis. Imatinib-induced exfoliative dermatitis usually occurs 1-3 weeks following initial exposure and within few hours to few days following a re-challenge. The exact mechanism of drug reaction is not known, but occurrence of eruption immediately after re-challenge suggest hypersensitivity rather than a pharmacological effect. [4]

In case of mild cutaneous adverse effects, imatinib need not be discontinued; such cases can be managed with antihistaminics and topical steroids. In some patients, a strategy of initial discontinuation of imatinib followed by restart with or without topical/systemic steroids can be useful. Severe adverse reactions necessitate discontinuation of the drug. Oral desensitization has been found to be successful in some patients with leukemia. [4] For imatinib-intolerant patients, dasatinib and nilotinib are the alternatives. [5]

Overall, the incidence of skin rash due to dasatinib and nilotinib is low in comparison with that due to imatinib. The reported incidence of maculopapular rash is ≤34% and 20% in patients on imatinib and nilotinib or dasatinib, respectively, whereas that of severe skin rash is 2% with imatinib therapy as compared to <1% with dasatinib and nilotinib. The incidence of cross-reactivity between imatinib and other tyrosine kinase inhibitors is very low. [5]

Thus, we report a rare case of imatinib-induced erythroderma, which required cessation of therapy. Dermatologists should be aware of imatinib as a cause of drug-induced erythroderma.

References
1.
Mathew T, Chandrashekar L, Pulimood S, Srivastava A. Imatinib induced erythroderma. Australas J Dermatol 2007;48:193-4.
[Google Scholar]
2.
Druker BJ, Lydon NB. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest 2000;105:3-7.
[Google Scholar]
3.
Prabhash K, Biswas G, Prasad N, Karant N, Sastry PS, Parikh PM. Imatinib-induced nail hyperpigmentation in chronic myeloid leukemia. Indian J Dermatol Venereol Leprol 2006;72:63-4.
[Google Scholar]
4.
Nelson RP Jr, Cornetta K, Ward KE, Ramanuja S, Fausel C, Cripe LD. Desensitization to imatinib in patients with leukemia. Ann Allergy Asthma Immunol 2006;97:216-22.
[Google Scholar]
5.
Hartmann JT, Haap M, Kopp HG, Lipp HP. Tyrosine kinase inhibitors - A review on pharmacology, metabolism and side effects. Curr Drug Metab 2009;10:470-81.
[Google Scholar]

Fulltext Views
118

PDF downloads
67
Show Sections